ELSEVIER

J Pharmacol Toxicol 42 (1999) 245–247

Journal of Pharmacological and Toxicological Methods

Author Index
Volumes 41 and 42

A
Adachi H, 41:147
Agersø H, 41:1
Aguirre-Bañuelos P, 42:79, 42:87
Akamatsu N, 41:33, 41:173
Alexander B, 41:55, 42:31
Alloui A, 42:163
Al-Mulla Hummadi YM, 41:167
Armour S, 42:199
Armour SL, 42:217
Aschhoff S, 41:189
Aslam M, 42:31
Azay J, 41:59

B
Baek W, 42:171
Bailey AM, 41:127
Bailey MJ, 41:27
Baker GB, 41:143
Baudet S, 42:21
Benjamin IS, 41:55, 42:31
Blednov YA, 41:91
Bolio N, 42:189
Browse DJ, 41:55
Burkhart W, 42:189

C
Cahard D, 41:59
Cassanas G, 41:59
Castañeda-Hernández G, 42:59, 42:67
Castillo-Henkel C, 42:73
Chen G, 42:199
Chen W-J, 42:199, 42:217
Codd EE, 42:127
Collister JP, 42:135
Connelly CD, 42:127
Costes G, 41:17
Coutts RT, 41:143
Crawford N, 42:121
Cros G, 41:59

D
Daitoku K, 42:149
Deisher TA, 42:157
de Jong PE, 41:69
de Vries DJ, 42:121
de Zeeuw D, 41:69
Diamond J, 42:49
Dickinson RG, 41:27
Drustrup J, 41:1

E
Ellsworth JL, 42:157
Eschalier A, 42:163

F
Farjou IB, 41:167
Flores-Murrieta FJ, 42:103
Foord S, 42:217
Fuentes-Lara G, 42:93
Fürst W, 41:9

G
García-López P, 42:93, 42:99
Garrido MJ, 42:61
Gaspo R, 42:11
Germann P-G, 41:97, 42:39
Ghosh D, 42:157
Goetz AS, 42:225
Granados-Soto V, 42:67, 42:79, 42:87
Guízar-Sahagún G, 42:93
Gupta A, 41:183

H
Haarh P-M, 41:1
Häfner D, 41:97, 42:39
Hallström S, 41:9
Hansen K, 41:153
Hennan JK, 42:49
Higaki T, 41:33, 41:173
Hoare SRJ, 41:83
Huber L, 41:9

1056-8719/99/$ – see front matter © 1999 Elsevier Science Inc. All rights reserved.
PII: S1056-8719(00)00094-0

I
Igić R, 41:161
Ignar D, 42:199
Ignar DM, 42:225
Imamura H, 41:33, 41:173
Ishihara H, 41:147
Islas-Cadena M, 42:87

J
Jain GK, 41:183
Jayawickreme C, 42:189, 42:199
Jiménez M, 42:103
Jones-Hertzog DK, 42:207
Jørgensen KD, 41:1
Jourdan D, 42:163

K
Keefer CE, 42:207
Kellogg DL Jr, 41:49
Kenakin T, 42:177, 42:199, 42:217
Kerr DS, 42:121
Kim I, 42:171
Kim J, 42:171
Kim M, 42:171
Kim Y, 42:171
Kodama K, 41:147
Komatsu S, 41:33, 41:173
Kono Y, 41:33, 41:173
Kröner A, 41:9
Krosniak M, 41:59

L
Lang TK, 42:121
Langerman L, 42:115
Laroute V, 41:17
Lefebvre HP, 41:17
Li QS, 42:127
Liacos J, 42:225
Liu YJ, 41:49

M
Margolis A, 42:115
Marks GS, 42:107
Marron B, 42:189
Mateos-García E, 42:73
Méchaly I, 41:59
Medina-Santillán R, 42:73
Moe SM, 41:127
Motomura S, 42:149
Moyer M, 42:189
Mukhopadhyay P, 42:207

N
Nägele U, 41:189
Najim RA, 41:167
Nakagawa K, 41:173
Nakagawa M, 41:33, 41:173
Navis G, 41:69
Nedergaard OA, 41:153
Newman LC, 41:43
Noireaud J, 42:21

O
O'Donnell D, 41:49
Osborn JW, 42:135
Osborne R, 42:1

P
Pache DM, 41:135
Pérez-Urizar J, 42:103
Perkins MA, 42:1
Po W, 41:161
Podesser BK, 41:9

Q
Queen K, 42:199

R
Raffa RB, 42:127
Raghubir R, 41:183
Reading SJ, 41:55
Remien J, 41:189
Reyes-García G, 42:73
Rimele T, 42:189
Rimele TJ, 42:175
Robinson MK, 42:1
Roque C, 41:59
Ruan J, 42:189

S
Salas R, 42:99
Salsali M, 41:143
Sato T, 41:33, 41:173
Sauls H, 42:189
Sawada S, 41:33, 41:173
Schima H, 41:9
Schoemaker RC, 41:107
Schroff K-C, 41:189
Schulze J, 41:189
Serrano JJ, 41:59
Sewell RDE, 41:135
Seya K, 42:149
Shaffer J, 42:189
Shepherd AMM, 41:49
Simpson VJ, 41:91
Spencer PSJ, 41:135
Stagni G, 41:49
Stam WB, 41:117
Steingart RA, 42:115
Stevens CW, 41:43

T
Tada Y, 41:33, 41:173
Tamagaki T, 41:33, 41:173
Teplitz L, 41:161
Terán-Rosales F, 42:73
Toratani A, 41:33
Toutain P-L, 41:17
Trocóniz IF, 42:61
Trzeciakowski JP, 41:75
Tsuda Y, 41:33, 41:173
Tsuji H, 41:33, 41:173

U
Usdin TB, 41:83

V
Van der Graaf PH, 41:107, 41:117
van Goor H, 41:69

W
Wallace DR, 41:43
Wapstra FH, 41:69
Watson C, 42:199
Way J, 42:199
Weisser J, 41:9
Wilken M, 41:1
Wolner E, 41:9
Wong SGW, 42:107

Y
Yamasaki S, 41:33, 41:173
Yanai J, 42:115
Yingling J, 42:225
Young SS, 42:207

ELSEVIER

J Pharmacol Toxicol 42 (1999) 249–251

Journal of Pharmacological and Toxicological Methods

Subject Index
Volumes 41 and 42

A
ACE-inhibition, 41:69
Acetylcholine, 41:153
Acute respiratory distress syndrome, 42:39
Acyl glucuronides, 41:27
Addiction, 42:115
α-Adrenoceptors, 42:237
α_1-Adrenoceptors, 41:107, 41:117
Adrenomedullin, 42:217
Adriamycin, 41:69
Affinity, 41:117
Agonist, 41:83
α[IFN]2-Agonists, 42:127
Amylin, 42:217
Analgesia, 42:67, 42:73
Analgesics, 42:127
Antagonist, 41:83
Anti-hGH, 41:1
Antibodies, 41:1
Antinociception, 42:67
Aorta, 42:171
ARDS-model, 41:97
Arterial pressure, 42:135
Arthritis, 41:127
Aspirin, 42:93
Atrial fibrillation, 42:11
Atrial tachycardia, 42:11
Autonomic nervous system, 42:135

B
Bioavailability, 42:93, 42:99
Blood pressure, 41:69, 42:127
Bone, 41:127
Bradykinin, 41:161
Brain perfusion, 42:31

C
Ca^{2+}, 41:173
Caffeine, 42:67
Calcitonin receptor, 42:217
Calcitonin receptor-like receptor, 42:217
Cavernous nerve, 41:147
Cell proliferation, 41:33
Cerebral glucose, 42:31
cGMP, 42:49
CGRP (calcitonin gene-related peptide), 42:217
Chronic animal models, 42:11
Clonazepam, 41:167
Combinatorial peptide library photo-cleavage, 42:189
Competitive polymerase chain reaction, 41:173
Computerized histomorphometry, 41:59
Concentration–response curves, 41:55
Constitutive receptor activity, 42:199
Contraction, 42:171
Contraction-relaxation coupling, 42:21
Coronary flow reserve, 41:9
Coronary occlusion, 42:149
Correlated data, 42:157
Culture model, 41:127
Curve fitting, 41:107, 42:21
Cyanocobalamin, 42:73
Cyclic GMP, 42:79, 42:87
Cytochrome P450, 42:107

D
Delayed matching to position, 41:135
Delayed non-matching to position, 41:135
Derived variables, 42:157
Dermis, 41:49
Desmethylimipramine, 42:149
Dexamethasone, 42:39
Dextromethorphan, 41:143
Dextrorphan, 41:143
Diabetes, 41:59
Diclofenac, 42:73, 42:99
Dihydropyridine, 42:107
[^{3}H]-diprenorphine, 41:43
Dipyrone, 42:79
Dog, 41:17
Domoic acid, 42:121
Dose–response, 42:157
Doxorubicin, 41:69
Doxycycline, 41:127
Drug efficacy, 41:55

1056-8719/99/$ – see front matter © 1999 Elsevier Science Inc. All rights reserved.
PII: S1056-8719(00)00093-9

Drug potency, 41:55
Drug–protein adducts, 41:27

E
EC_{50}, 41:55
Effective renal plasma flow, 41:17
Efficacy, 41:117
EKG, 42:127
Electron-capture gas chromatography, 41:143
Endothelium, 41:153
Epinephrine, 41:161
Erythrocyte, 41:9
Ethanol, 41:167
Ex vivo microdialysis, 42:149
Experimental porphyria, 42:107

F
Filter binding, 42:237
Fluorescent probes, 42:225
Formalin test, 42:163
Frequency histogram, 41:75
Furchgott method, 41:117

G
Ganglionic blockade, 42:135
Gas chromatography/mass spectrometry, 41:91
Gas exchange, 41:97
Gastric damage, 41:167
Gaussian distribution, 41:75
Glomerular filtration rate, 41:17
Glomerulosclerosis, 41:69
Gompertz model, 41:107
G-protein–coupled receptors, 41:83, 42:189, 42:199, 42:207, 42:225

H
Heart rate, 42:127
Heat shock, 42:171
Heat shock protein, 42:171
Hepatocytes, 41:27
High-performance liquid chromatography, 41:17
Hill equation, 41:107
Histopathological changes, 41:97
Hyaline membranes, 42:39
Hydrocortisone, 41:183
Hydroxyproline, 41:183

I
Immunocompromised, 41:183
Immunosuppressant treatment, 41:1
Immunosuppressed pig model, 41:1
In vitro, 41:167
In vitro assay, 42:121
Indexes, 42:21
Indomethacin, 41:127
Intracellular calcium handling, 42:21
Intracellular pH, 41:33
Iohexol, 41:17
Iontophoresis, 41:49
Isolated, blood-perfused papillary muscle (PM) preparation of dog, 42:149
Isolated "working" heart, 41:161
Isometric relaxation, 42:21

K
Kainic acid, 42:121
Ketamine assay, 41:91

L
Lavage volume, 41:97
LDL, 41:33
Lead finding, 42:207
Ligand binding, 41:83
Lisinopril, 41:69
Liver perfusion, 42:31
L-NAME, 42:79, 42:87
Logistic model, 41:107
Longitudinal data, 42:157

M
Mechanism-based inactivation, 42:107
Melanophore, 42:189, 42:217
Mesenteric arteries, 41:59
Methadone, 42:61
Method, 42:127
Mice, 42:115
Microdialysis, 41:49
Mixed-effects model, 42:157
Morphine, 42:79, 42:115
Mouse brain assay, 41:91
α-MSH, 42:189
Myofibrillar calcium responsiveness, 42:21

N
N-alkylprotoporphyrin IX, 42:107
Naloxone, 42:79
Naltrexone, 41:43
Nephrosis, 41:69
Neutrophil leukocytes, 42:39
Nimesulide, 42:87
Nitric oxide, 41:147, 42:49, 42:79, 42:87
Nonlinear mixed effect modelling, 41:107
Nonsteroidal anti-inflammatory drugs, 42:67
Noradrenaline, 41:117
Normalization, 41:75

O
ODQ, 42:87
8-OH-DPAT, 41:135
Operational model of agonism, 41:117
Opioids, 42:61, 42:115

P
Pain, 42:163
Papillary muscle, 42:21
Para-aminohippuric acid, 41:17
Parathyroid hormone, 41:83
Pathophysiologic alterations, 42:11
Penile diameter, 41:147
Penile erection, 41:147
Pentafluorobenzoyl chloride, 41:143
PGHS, 41:173
PGI_2, 41:173
Pharmacodynamics, 42:61
Pharmacokinetic/pharmacodynamic, 41:91
Pharmacokinetics, 41:1, 41:17, 42:61, 42:99, 42:103
Phenoxybenzamine, 41:117
Phosphodiesterase 5 inhibitor, 41:147
Phosphorylation, 42:49
Physiology, 41:9
PLA_2, 41:173
Portal-systemic encephalopathy, 42:31
Probability density, 41:75
Probucol, 41:33
Prostacyclin, 41:33
Proteinuria, 41:69
Pulmonary gas exchange, 42:39
Pyridoxine, 42:73

R
Rabbit, 42:21
Rabbit aorta, 41:153
Radioligand binding, 42:121
RAMP (receptor-activity-modifying protein), 42:217
Rana pipiens, 41:43
Rapid atrial pacing, 42:11
Rat, 41:161, 41:167, 42:103, 42:127, 42:163
Reactivity, 41:27
Receptor screening, 42:199
Recursive partitioning, 42:207
Reporter gene, 42:225
Response curves, 41:75
Richards model, 41:107
rSP-C, 41:97, 42:39

S
Salicylic acid, 42:93
Scintillation-proximity assay (SPA), 42:237
Scopolamine, 41:135
Sequential screening, 42:207
Sex, 42:103
Short-term memory function, 41:135
Skin blood flow, 41:49
Small mesenteric artery (rat), 41:117
Smooth muscle, 42:49
Sodium fluorescein, 41:49
Spinal cord injury, 42:93, 42:99
Statistics, 41:75
Subendocardial interstitial norepinephrine, 42:149
Surfactant treatment, 41:97
Sydnone, 42:107
Synoviocytes, 41:127
Synthetic surfactant, 42:39

T
Technical approaches, 42:11
Thiamin, 42:73
Thrombin, 41:173
Tolmetin, 42:103
Two-dimensional gel electrophoresis, 42:49

V
Vasodilatation, 41:153
Vasopressin, 41:59
Vitamin B, 42:73

W
Wall stress-induced dysrhythmias, 41:161
Withdrawal, 42:115
Working heart preparation, 41:9
Wound, 41:183

Z
Zomepirac, 41:27